NCT00872586 - Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension | Biotech Hunter

Enrollment

304

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

August 31, 2007

Conditions

Essential Hypertension

Interventions

DRUG

olmesartan medoxomil + hydrochlorothiazide

olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks

DRUG

olmesartan medoxomil

olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks

Trial Locations (8)

Unknown

Beijing

Chengdu

Chongqing

Guangzhou

Hangzhou

Nanjing

Shanghai

Wuhan